J&J's new multiple myeloma fighter gets FDA priority review

The FDA put Johnson & Johnson's ($JNJ) new multiple myeloma treatment into the priority review lane for approval. The drug, daratumumab, is up for a green light for patients with hard-to-treat disease, or who have failed on at least two standard types of therapy. The anti-CD38 antibody could be a first-in-class treatment for the disease; the agency's decision deadline is in March 2016. Release